DiscoverMedEdTalks - GastroenterologyEfficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti
Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Update: 2021-03-16
Share

Description

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Dr. William J. Sandborn